Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio EssenceBIOE 31 EV-to-FCF is 11.98 as of Jul. 14, 2026. GuruFocus rates BIOE with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 562 Drug Manufacturers companies, Bio Essence ranks better than 72.95% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bio Essence's Enterprise Value is $14.18 Mil.
Bio Essence's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $1.18 Mil. Therefore, Bio Essence's EV-to-FCF for today is 11.98.
The historical rank and industry rank for Bio Essence's EV-to-FCF or its related term are showing as below:
BIOE'
s EV-to-FCF Range Over the Past 10 Years
Min: -32420.24 Med: -13.95 Max: 25.09
Current: 11.98
During the past 7 years, the highest EV-to-FCF of Bio Essence was 25.09. The lowest was -32420.24. And the median was -13.95.
BIOE's EV-to-FCF is ranked better than 72.95% of 562
companies
in the Drug Manufacturers industry
Industry Median: 21.055
vs BIOE: 11.98
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bio Essence's PE Ratio (TTM) for today is calculated as:
Bio Essence's share price for today is $0.2703.
Bio Essence's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bio Essence EV-to-FCF Related Terms
Bio Essence EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bio Essence's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bio Essence's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Essence EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bio Essence's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bio Essence's EV-to-FCF falls into.
Bio Essence's current Enterprise Value is $14.18 Mil.
Bio Essence's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Essence (BIOE) has a EV-to-FCF of 11.98 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bio Essence and its competitors. According to the industry distribution chart, Bio Essence ranks #152 out of 562 companies in the Drug Manufacturers industry, placing it in the top 27%.
Is Bio Essence's EV-to-FCF too high?
Bio Essence's current EV-to-FCF is 11.98. The Drug Manufacturers industry median EV-to-FCF is 21.06. Bio Essence's value of 11.98 is 43.1% below this industry median. Based on the distribution chart, Bio Essence ranks #152 out of 562 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bio Essence has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Bio Essence's EV-to-FCF compare to BFRI and APUS?
According to the Drug Manufacturers industry distribution chart, Bio Essence ranks #152 out of 562 companies for EV-to-FCF. This puts Bio Essence in the upper half of its industry. The industry median EV-to-FCF is 21.06. Bio Essence's value of 11.98 is 43.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.06, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Essence's current EV-to-FCF of 11.98 is 43.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bio Essence and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Essence's current EV-to-FCF is 11.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Essence stock overvalued right now?
Bio Essence (BIOE) has a current EV-to-FCF of 11.98. The current EV-to-FCF is 11.98 and 43.1% below the Drug Manufacturers industry median of 21.06. Bio Essence's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bio Essence (BIOE), the current EV-to-FCF is 11.98 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Essence Corp is an herbal health, diet, and nutrition company. The Company's mission is to provide herbal health, diet, and vitamin nutritional supplements. The primary focus of BEP was producing products for BEH and McBE, along with providing original equipment manufacturing and private label services to other companies. BEH targeted and developed traditional Chinese medicines (TCM) in the form of single herbs, granules, pills, and tablets. It also offered specially formulated dietary supplements and medical food. The Company operates in one business and industry segment: the manufacture / OEM and sale of health supplement products. The group's products are RED Yeast Rice Plus, Regenva, MediDrink, and Nufargo.
31GF Score
Get the complete analysis for BIOE
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOE has been successfully added to your 
